LATEST

• COMMENTARY ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
  March 9, 2026

• REGULATORY MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
  March 9, 2026

• REGULATORY MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
  March 9, 2026

• BUSINESS Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
  March 9, 2026

• BUSINESS Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
  March 9, 2026

• BUSINESS Towa Broadens Label for Tacrolimus in Cell Transplantation
  March 9, 2026

• REGULATORY Japan Health Minister Lauds Approval of iPSC-Based Therapies
  March 9, 2026

• BUSINESS Japan Ethical Drug Sales Up 1.2% in January: Crecon
  March 9, 2026

• REGULATORY Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
  March 6, 2026

• REGULATORY Forxiga Slapped with 36% Price Cut on PMP Return in FY2026 Revision
  March 6, 2026

• BUSINESS Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
  March 6, 2026

• REGULATORY Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
  March 6, 2026

• BUSINESS Japan Grants First-Ever Approval to iPSC-Based Therapies
  March 6, 2026

• REGULATORY Japan's Revised Drug Distribution Guidelines Take Effect
  March 6, 2026

• BUSINESS Meiji Starts Japan PIII Trial of Rezurock for CLAD
  March 6, 2026

• BUSINESS Meiji Rolls Out Rezurock in Taiwan
  March 6, 2026

• BUSINESS Toray Out-Licenses Parkinson’s Drug to Immunis
  March 6, 2026

• BUSINESS Sawai Pharmaceutical to Promote Toshiomi Nakate to President
  March 6, 2026

• BUSINESS Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
  March 6, 2026

• BUSINESS Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
  March 6, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• …
• Next ›
• 最終 »